2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Why the study?
Heart failure remains a leading cause of morbidity and mortality globally, requiring updated, patient-centric recommendations based on contemporary evidence to prevent, diagnose, and manage patients.
Population
Patients with heart failure
Design
Clinical practice guideline
Discussion
Loading...
Member takes
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
BBBiykem BozkurtProfessor of Medicine, Baylor College of Medicine
“We have four medications to save lives and improve outcomes more than ever, and that therapy is standard core therapy with four drug classes... that can be initiated and optimized as soon as possible: that should be clear. Every patient with reduced EF should have optimization of these four classes.”
“One primary goal with the new guideline was to use recently published data to update our recommendations for the evaluation and management of heart failure. One focus was prevention of heart failure through optimizing blood pressure control and adherence to a healthy lifestyle.”
BBBiykem BozkurtProfessor of Medicine, Baylor College of Medicine
“We have very important updates to the recommendations, including quadruple classes of medications indicated for patients with HF with reduced ejection fraction. These include SGLT2 inhibitors, along with beta-blockers, mineralocorticoid receptor inhibitor antagonists (MRA), renin-angiotensin-aldosterone inhibition with angiotensin receptor neprilysin inhibitors (ARNI), angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers.”
Implication
Updates HF prevention, diagnosis, and management recommendations; extends 2013/2017 guidelines with evidence through 2020.
Key Points
- The guideline aims to provide updated, patient-centric recommendations to effectively manage heart failure.
- Conducted a comprehensive literature search from May 2020 to December 2020.
- Included studies, reviews, and evidence published in English across various medical databases.
- Aligned with other AHA/ACC guidelines published through December 2021.
- Includes updated treatment recommendations based on contemporary evidence for managing heart failure patients.
- Introduces new recommendations supported by recent published data.
- Offers value statements for treatments informed by high-quality economic analyses.
Structured PICO
P
Population
Patients with heart failure
I
Intervention
Evidence-based recommendations for the prevention, diagnosis, and management of heart failure
This executive summary outlines the updated 2022 AHA/ACC/HFSA clinical practice guidelines for the prevention, diagnosis, and management of heart failure.
Cite This Study
A 2022 study conducted a review in Heart failure. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure was evaluated. The 2022 AHA/ACC/HFSA Guideline provides updated, evidence-based recommendations for clinicians to prevent, diagnose, and manage patients with heart failure.